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Background: miRNA profiles are promising biomarker candidates for a manifold of human pathologies, opening
new avenues for diagnosis and prognosis. Beyond studies that describe miRNAs frequently as markers for specific
traits, we asked whether a general pattern for miRNAs across many diseases exists.
Methods: We evaluated genome-wide circulating profiles of 1,049 patients suffering from 19 different cancer and
non-cancer diseases as well as unaffected controls. The results were validated on 319 individuals using qRT-PCR.
Results: We discovered 34 miRNAs with strong disease association. Among those, we found substantially decreased
levels of hsa-miR-144* and hsa-miR-20b with AUC of 0.751 (95% CI: 0.703–0.799), respectively. We also discovered a
set of miRNAs, including hsa-miR-155*, as rather stable markers, offering reasonable control miRNAs for future
studies. The strong downregulation of hsa-miR-144* and the less variable pattern of hsa-miR-155* has been
validated in a cohort of 319 samples in three different centers. Here, breast cancer as an additional disease
phenotype not included in the screening phase has been included as the 20th trait.
Conclusions: Our study on 1,368 patients including 1,049 genome-wide miRNA profiles and 319 qRT-PCR
validations further underscores the high potential of specific blood-borne miRNA patterns as molecular biomarkers.
Importantly, we highlight 34 miRNAs that are generally dysregulated in human pathologies. Although these markers
are not specific to certain diseases they may add to the diagnosis in combination with other markers, building a
specific signature. Besides these dysregulated miRNAs, we propose a set of constant miRNAs that may be used as
control markers.
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In the past decade, non-coding miRNAs have aroused
scientists’ interest and their exploration has revolutio-
nized biology. Since the first miRNA was discovered in
Caenorhabditis elegans in 1993 [1], an increasing num-
ber of miRNAs for various species have been reported.
Currently, release 20 of the miRBase [2,3] contains 24,521
entries representing hairpin precursor miRNAs, express-
ing 30,424 mature miRNA products in 206 species. For* Correspondence: ack@bioinf.uni-sb.de
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unless otherwise stated.Homo sapiens, more than 2,500 different mature miRNAs
are currently included in this database.
The small non-coding miRNAs are known to be
involved in crucial biological processes such as prolife-
ration, apoptosis, differentiation, or development [4-6].
More than 50% of all genes in the human genome are
known to be miRNA targets and, thus, miRNAs are
involved in the regulation of a manifold of metabolic
and regulatory pathways such that now the integrative
network analysis of miRNAs and mRNAs becomes more
and more possible [7-9]. Hence, abnormal miRNA pro-
files have been associated with many human pathogenic
processes as shown by many studies that focused on
tissue-derived miRNA profiles (e.g., from patients withtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Since these small nucleic acids excel in their high stability,
they have become even more attractive as biomarker
candidates. This also underlines the potential of miRNA
biomarkers derived from peripheral blood for diagnostic
purposes. Many groups investigated circulating miRNA
profiles from serum for various diseases (non-ischemic
systolic heart failure [13], pulmonary tuberculosis [14],
non-small-cell lung cancer [15,16], breast cancer [17],
prostate cancer [18], or ovarian cancer [19]), whereas we
and others developed standardized operating procedures
for measuring miRNA profiles from whole peripheral
blood (myocardial infarction [20], lung cancer [21], mul-
tiple sclerosis [22,23], melanoma [24], ovarian cancer [25],
chronic obstructive pulmonary disease [26], glioblastoma
[27], and Alzheimer disease [28]).
In the present meta-analysis, we analyzed a total of 848
miRNAs in 1,049 samples (containing the 454 samples
published in our previous study [29]) measured fromTable 1 Cohorts with International Classification of Diseases (
Disease ICD-10
Normal –
Long-lived individuals –
Tumor of stomach C16
Colon cancer C18
Lung cancer C24
Pancreatic ductal adenocarcinoma C25
Melanoma C43
Ovarian cancer C56
Prostate cancer C61
Wilms tumor C64
Renal cancer C65
Glioma C71
Sarcoidosis D86.0
Multiple sclerosis G35
Acute myocardial infarction I21.3
Non-ischemic systolic heart failure I42
Chronic obstructive pulmonary disease J40-47
Peridontitis K05.4
Pancreatitis K85
Psoriasis L40
Benign prostate hyperplasia N40
Others –whole blood collected in PAXgene blood tubes. The
investigated cohort includes healthy controls as well as
patients diagnosed with one of 19 diseases of different
International Classification of Diseases (ICD)-10 classes
(10 cancer entities and 9 non-cancer diseases; details
on the different cohort sizes are presented in Table 1).
Our results provide a comprehensive overview of the
human disease miRNome. By using this rich data source,
we aimed at identifying miRNA profiles representative for
a general disease state, and to identify miRNA signatures
that are suited to discriminate different diseases from
controls and from each other.
Methods
Blood samples and groups
The blood samples were collected and processed from
nine different institutions (Table 1). Five centers provi-
ded samples from individuals with disease as well as
controls. Blood was collected in PAXgene Blood RNAICD)-10 code and cohort sizes
# Samples Institution providing RNA
94 Saarland University
DKFZ/Heidelberg University
Heidelberg University
Julius-Maximilians-University Wuerzburg
Zürich University
Christian-Albrechts-University Kiel
15 Christian-Albrechts-University Kiel
13 DKFZ/Heidelberg University
29 Saarland University
73 Saarland University
45 DKFZ/Heidelberg University
35 Saarland University
24 Julius-Maximilians-University Wuerzburg
65 Saarland University
124 Saarland University
20 Saarland University
20 Zürich University
45 Albrecht Ludwigs University, Freiburg
23 Saarland University
62 Heidelberg University
33 Heidelberg University
47 Saarland University
18 Christian-Albrechts-University Kiel
37 DKFZ/Heidelberg University
43 Saarland University
35 Saarland University
149
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ing in this study gave their informed consent and local
ethics committees (Ethics Commission at the Friedrich-
Alexander University Erlangen-Nürnberg Medical School;
Ethics Commission of the Christian-Albrechts-University
Kiel; Ethics Committee at the University of Würzburg
Medical School; Ärztekammer des Saarlandes; Ethics
Committee Heidelberg University) approved the studies.
An overview of all patients is presented in Additional
file 1: Table S1. Selected diseases/traits have been grouped
together as “others”. This includes patients with unclear
diagnosis, e.g., patients that have either a pancreatic
cancer or pancreatitis or patients with prostate cancer
or benign prostate hyperplasia. The “others” group also
contains some very small cohorts, e.g., 6 samples with
“atopic dermatitis”. One group has been left out of the
pairwise comparisons, namely the 15 long-lived individ-
uals that show a substantial age bias since these would
potentially bias either the control or disease profiles.
miRNA extraction and microarray screening
miRNA extraction and microarray measurement have
been carried out as previously described [29]. The full data
set has been deposited in the gene expression omnibus
under reference GSE61741.
Statistical analysis
All statistical computations were carried out using the
publicly available statistical language R [30]. For each
miRNA, we report median expression in the respective
groups, together with fold changes. Beyond this infor-
mation, the variability of miRNAs is of high importance.
Thus, we calculated measures that also depend on the
variance. To assess the information content of single
miRNAs and miRNA profiles, the area under the receiver
operator characteristics (ROC) curve (AUC) was com-
puted using the pROC package. The 95% confidence inter-
vals for the ROC curves and AUC values were calculated
using 2,000 bootstrap samples. To determine significance
values for miRNAs, two-tailed unpaired t-tests were calcu-
lated and the significance values adjusted for multiple test-
ing using the Benjamini-Hochberg approach. Validated
target miRNAs by reporter assays have been extracted
from miRTarBase [31,32]. Pathway enrichment analysis
has been carried out using our tool GeneTrail [33,34].
Visualization has been done using CytoScape.
Machine learning analysis
Supervised classification of samples was carried out using
linear Support Vector Machines (SVM) as implemented
in the R e1071 package. SVMs were evaluated by applying
standard 10-fold cross-validation and a stepwise-forward
filter subset selection technique. In order to account for
variations in the random partitioning into sample subsets,cross-validation runs were repeated 10 times. Moreover,
to test for potential overtraining, exactly the same proced-
ure was carried out using randomly permuted class labels,
such that 10 so-called permutation tests were applied for
each subset size. All classifications were carried out with
equal cohort sizes, i.e., if one group was larger than the
other, samples from the first group were randomly
selected in each repetition in order to simulate the same
cohort sizes.
qRT-PCR validation
qRT-PCR was performed in two participating centers
(center 1: Heidelberg University, center 2: Saarland Uni-
versity) using the miScript PCR System (Qiagen) and the
primer assays for hsa-miR-144* and hsa-miR-155*. We
analyzed the expression of these two miRNAs in a total
of 282 samples (center 1: 172 samples from controls, and
patients with acute myocardial infarction, non-ischemic
systolic heart failure, glioblastoma, pancreatic diseases,
and breast cancer; center 2: 110 samples from controls,
and patients with Wilms tumor, psoriasis, renal cancer,
prostate cancer, lung cancer, multiple sclerosis, benign
prostate hyperplasia, colon cancer, and chronic obstructive
pulmonary disease). Additionally, a third cohort was
included, providing 37 samples of a breast cancer study, a
phenotype that was not included in the screening. As
endogenous control, RNU6B was measured. To analyze
qRT-PCR data we applied relative quantification using
the 2−ΔΔCT method [35].
Results
Identification of miRNAs generally indicating the
presence of a disease
We asked if there is a general association between the
expression of certain miRNAs in peripheral blood and
the presence of a disease. To this end, we calculated a
two-tailed unpaired t-test of all patients versus all controls
and adjusted the significance values for multiple testing.
Furthermore, we calculated for each miRNA separately
the AUC together with the respective 95% confidence
intervals. For the comparison of diseases (cancer and non-
cancer samples) versus healthy controls, we found 333
statistically significantly dysregulated miRNAs (adjusted
P <0.05), of which 254 were upregulated in diseases while
only 79 were downregulated. The most significant miRNA
hsa-miR-576-5p reached an adjusted significance value
of 4.7 × 10−16 (raw P =5.6 × 10−19). The miRNAs hsa-
miR-144* and hsa-miR-20b were the most downregulated
with an AUC of 0.751 (95% CI: 0.703–0.799), followed by
miR-17 and miR-20a. For the first two miRNAs, ROC
curves are presented in Figure 1. In contrast, hsa-miR-720
was the most upregulated with an AUC value of 0.68,
followed by hsa-miR-302c. All AUC and P values for this
comparison are provided in Additional file 1: Table S2. As
Figure 1 ROC curves for disease specific miRNAs. (A) The ROC curve for hsa-miR-144* is shown. (B) The ROC curve for hsa-miR-20b is shown.
The blue shaded area denotes the 95% confidence interval computed by 2,000 bootstrap samples.
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5p, had a median expression close to the background.
However, interpreting the actual expression values it can
be seen that many patients partially demonstrate a very
high expression of that miRNA. Here, the mean value of
the samples may help to interpret the expression level and
differences in miRNA abundance. For controls, the mean
of this miRNA is 5.4, signifying an expression level close
to the background. However, for patients, the mean is
clearly above the background with a value of 21.4, i.e., four
times higher as for controls. This may indicate that such
generally low abundant miRNAs may have an influence
on diseases.
Focusing on onco-miRNAs by comparing cancer sam-
ples versus healthy controls we found 322 miRNAs with
adjusted t-test P <0.05, of which 101 were downregu-
lated in cancer while 221 were upregulated. The most
significantly dysregulated miRNA, hsa-miR-130b*, reached
an adjusted significance value of 1.9 × 10−14 (raw P =2.2 ×
10−17). In this analysis, again hsa-miR-144* and hsa-miR-
20b showed the strongest downregulation in diseases with
AUC values of 0.771 (95% CI of 0.721–0.821) and 0.760
(95% CI of 0.71–0.811), respectively, while hsa-miR-194*
was the most upregulated miRNA with an AUC value of
0.687. All AUC and P values for this scenario are provided
in Additional file 1: Table S3.
Notably, both comparisons described above showed a
high concordance, demonstrated by a correlation of 0.95
of the AUC values and the significant overlap presented
in the Venn diagram (Figure 2). This result indicates that
most miRNAs are not specific for cancer but for diseases
in general. Thus, it is not surprising that the maximal
AUC between all cancer and non-cancer diseases com-
puted for hsa-miR-574-5p was just 0.63 and is thus sub-
stantially smaller than the AUCs for the comparisonof diseases versus healthy control samples. Likewise, we
found a decreased number of miRNAs significant for this
comparison. Altogether, just 116 miRNAs reached a sig-
nificance value of below 0.05 and remained significant
after adjustment for multiple testing. Of these, 61 were
downregulated in cancer and 55 were upregulated. All
AUC and P values for this comparison are provided in
Additional file 1: Table S4.
Disease-specificity of single miRNAs
As described above we found many miRNAs being dys-
regulated in diseases in general. To further explore this
we asked how specific miRNAs are with respect to a
specific disease, e.g., whether they are upregulated in one
group and downregulated in another group of diseases.
First, we compared all diseases separately against controls.
Of all miRNAs, seven (hsa-miR-380*, hsa-miR-106b, hsa-
miR-17, hsa-miR-144*, hsa-miR-558, hsa-miR-548d-3p,
and hsa-miR-222) were significantly downregulated (ad-
justed two-tailed t-test P <0.05) in at least 13 of 19 disease
conditions, representing the most non-specific miRNAs.
A further 6 miRNAs were significantly downregulated in
12 pathologies, 7 miRNAs were downregulated in 11
pathologies, and 6 miRNAs were downregulated in 10
diseases while not being upregulated in any other. Con-
versely, three miRNAs (hsa-miR-130b*, hsa-miR-145,
and hsa-miR-658) were upregulated in 11 diseases while
not being downregulated in any other. Additionally, 9
miRNAs (hsa-miR-484, hsa-miR-499-5p, hsa-miR-126*,
hsa-miR-491-5p, hsa-miR-1303, hsa-miR-539, hsa-miR-25*,
hsa-let-7e*, and hsa-miR-194*) were upregulated in 10
diseases while not downregulated in any other, as the bal-
loon plot (Figure 3) of all miRNAs significant in at least 8
of 19 diseases (>40%) shows. The balloon plot size re-
presents the number of miRNAs that show significant
Figure 3 Up- versus downregulations. The balloon plot shows, for the different miRNAs, how many diseases the miRNAs are up- and respectively
downregulated in. The bubble size represents the number of miRNAs showing this distribution in up- and downregulation. Orange bubbles belong to
predominantly downregulated while blue bubbles belong to predominantly upregulated miRNAs. The two green bubbles represent 9 miRNAs that
were equally up- and downregulated in disease.
Figure 2 Area-proportional Venn diagram for miRNAs with the highest AUC values in the comparisons of diseases versus healthy
controls and cancer versus healthy controls. Green area shows upregulated miRNAs while red area shows downregulated miRNAs in cancer
and diseases in general. Both comparisons show a high overlap of dysregulated miRNAs, the respective miRNAs are presented on the left and
right of the Venn diagram.
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number of diseases. The largest bubble at position (8,0)
represents 22 miRNAs that are downregulated in 8 dis-
eases but not upregulated in a single disease. Altogether,
249 miRNAs are contained in the balloon plot. The
respective markers can be found in Additional file 1:
Table S5. Our results also provide strong evidence that
up- and downregulation of miRNAs in diseases are
anti-correlated, i.e., the dysregulated miRNAs are either
up- or downregulated in diseases generally but very few
miRNAs are upregulated in several diseases while
downregulated in others. In our initial study [29], 62
miRNAs were found to be associated with over 40% of
all tested disease conditions. Of these 62 miRNAs, 39
were found to be still dysregulated in at least 40% of all
diseases despite our substantial extension of the study.
Importantly, we found a substantial variance in miRNA
expression related to human pathologies. Considering sin-
gle diseases, we found the highest number of 408 signifi-
cantly dysregulated miRNAs in the case of colon cancer
and melanoma. The lowest number with 115 dysregulated
miRNAs was detected for pancreatitis. For each disease,
we were furthermore able to detect a unique signature,
i.e., a combination of significant miRNAs that did not
overlapped with any other signature, allowing for specific
differentiating between normal controls and diseases.
Besides the comparison between controls and diseases
we also asked for specific signatures between diseases
overall. Altogether, our study includes 20 different clas-
ses, 19 diseases as well as controls. Thus, a total of 190
specific signatures, one for each possible pair of the 20
cohorts, can be calculated. We carried out all compari-
sons and computed the number of miRNAs significant
in each comparison as well as the number of compari-
sons where a certain miRNA was found to be signifi-
cant. Thereby, we detected an average of 256 significant
miRNAs per comparison. While some miRNAs were
significant in many scenarios (including hsa-miR-106a
(130 comparisons), hsa-miR-361-5p (130 comparisons),
hsa-miR-17 (125 comparisons), hsa-miR-423-5p (125
comparisons), hsa-miR-320d (122 comparisons), and hsa-
miR-20a (120 comparisons)), others were significantly
dysregulated in just a few comparisons (including hsa-
miR-506 (3 comparisons), hsa-miR-202* (5 comparisons),
hsa-miR-361-3p (6 comparisons), hsa-miR-429 (7 compa-
risons), hsa-miR-548a-3p (9 comparisons), or hsa-miR-
518e (9 comparisons)). All disease-specific signatures are
detailed in Additional file 1: Table S5. In particular, the
miRNAs that are significant in many different compari-
sons show a substantial data variance. To further evaluate
this, we carried out an analysis of variance (ANOVA).
Even after adjustment for multiple testing all but 19
miRNAs (2.2%) were significant in our ANOVA. The
highest significance was reached for hsa-miR-151-3p(P = 4.03 × 10−89). Among the most significant miRNAs in
the ANOVA was also hsa-miR-144*, being significant in
14 different diseases and representing the most gener-
ally dysregulated miRNA with a significance value of
1.88 × 10−33. Among the miRNAs with higher signifi-
cance values, we found hsa-miR-155* to be significantly
downregulated in just two diseases, namely acute myo-
cardial infarction and glioma.
qRT-PCR validation of microarray data
To validate our microarray results for two important
disease miRNAs, hsa-miR-144* (non-specific) and hsa-
miR-155* (specific), qRT-PCR was performed in two par-
ticipating centers. Center 1 (Heidelberg University) ana-
lyzed a total of 172 samples from controls and patients
with acute myocardial infarction, non-ischemic systolic
heart failure, glioblastoma, and pancreatic diseases. Center
2 (Saarland University) analyzed a total of 110 samples
from controls and patients with Wilms tumor, psoriasis,
renal cancer, prostate cancer, lung cancer, multiple scler-
osis, benign prostate hyperplasia, colon cancer, and chro-
nic obstructive pulmonary disease samples.
For miR-144*, we measured ΔΔCT values of −1.93 in
center 1. Thus, hsa-miR-144* was downregulated 3.8-fold
in diseases (P =1.9 × 10−5). In center 2, we calculated
ΔΔCT values of −1.75; thus, concordantly hsa-miR-144*
was significantly less expressed in diseases (P = 0.0096)
with a fold-change of 3.4.
As an independent set of patients and controls, we
selected a third cohort of samples, containing blood
samples from controls and from breast cancer patients.
Notably, this validation was independent, in that the
phenotype has not been included in the initial micro-
array screening and, likewise, this center had not con-
tributed any samples to the initial screening (sample
details are provided in Additional file 1: Table S6). The
qRT-PCR was performed from center 1. The ΔΔCT
value was −1.79. As for the first two validation approa-
ches, hsa-miR-144* was significantly less (P =0.04) ex-
pressed with a fold-change of 3.5 in breast cancer samples
compared to controls. In summary, we were able to
successfully validate that hsa-miR-144* was significantly
downregulated in various diseases in a total of 319 sam-
ples over three approaches with consistent fold-changes
of 3.8, 3.4, and 3.5, respectively.
Analogously to hsa-miR-144* as a general disease
marker, we also validated the miRNA hsa-miR-155* as
example of a rather specific miRNA. In our microarray
experiments hsa-miR-155* was only significantly down-
regulated in two diseases, namely acute myocardial in-
farction and glioma. The validation in center 1 reached
a highly significant P value of 3.66 × 10−6, showing a sig-
nificant downregulation of this miRNA in diseases (on
average 2.8-fold). Remarkably, as mentioned above the
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myocardial infarction samples and glioma samples, as well
as non-ischemic systolic heart failure and pancreatic dis-
eases. However, in discordance with the screening results,
we also found downregulation of miR-155* for pancreatic
diseases. In the second validation in center 2, analyzing
besides controls the diseases Wilms tumor, psoriasis, renal
cancer, prostate cancer, lung cancer, multiple sclerosis, be-
nign prostate hyperplasia, colon cancer, melanoma, and
chronic obstructive pulmonary disease we found a slight
upregulation of has-miR-155* at a moderate fold-change
of 1.7 with a non-adjusted significance value of 0.008.
After adjusting for multiple testing, only one of the 10
tested diseases (prostate cancer) remained significant. For
the breast cancer samples against controls we likewise did
not detect any statistically significant difference (P =0.42),
providing evidence that hsa-miR-155* is in contrast to
hsa-miR-144*, and is not a general disease marker but
only significant in a restricted subset of diseases.
Improvement of AUC values by combining multiple
miRNAs
As demonstrated, miRNAs have the potential to diffe-
rentiate between controls and patients in general with
high AUC values up to 0.75. By combining the predictiveFigure 4 Classification in patients (cancer and non-cancer) and contro
specificity, and sensitivity for the 10 repeated cross validations in red and f
above the horizontal black line are considered as patients (denoted by 2) apower of different miRNAs it can be expected that the
diagnostic power increases. To test this hypothesis we
employed a machine learning procedure. We applied a
stepwise forward subset selection approach with radial
basis function SVM and carried out 10 random repeti-
tion of 10-fold cross-validation.
For the classification in control and disease samples
we reached maximal AUC values of 0.911, as the ROC
curve in Figure 4A demonstrates. Our classifier outper-
formed the maximal AUC of the best single biomarker,
i.e., hsa-miR-144* and hsa-miR-20a (AUC 0.751, respect-
ively), by 16%. Altogether, we reached classification accur-
acy, specificity and sensitivity of 78%, 81%, and 75%, as the
box-plot in Figure 4B details. These results are signifi-
cantly improved as compared to random permutation
tests, presented as blue boxes in Figure 4B (P <10−10).
Figure 4C presents the classification example leading to
the best AUC of 0.911, providing evidence that the ma-
jority of the samples have been classified correctly.
For the comparison of cancer versus controls the highest
AUC was as high as 0.94, representing a 16.9% improve-
ment over the best single miRNA for this comparison
(hsa-miR-144*). Overall, a classification accuracy of
82%, a specificity of 81%, and a sensitivity of 83% were
reached.ls. (A) ROC curve for the best classification. (B) Box-plots for accuracy,
or 10 permutation tests in blue. (C) The best classification. Samples
nd below the black line as controls (denoted by 1).
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To gain insights into the molecular function of the
miRNAs, we carried out a network analysis. First, we
extracted all targets of the 34 miRNAs that are associ-
ated with diseases in general. Since in silico predictions
may show many false positive interactions or miss iden-
tifying actual miRNA-target gene relations we consid-
ered only experimentally validated targets. Specifically,Figure 5 miRNA-target gene network. miRNAs are shown as orange nod
blue nodes. The node size corresponds to the degree of the respective no
many disease-related miRNAs, are of interest.we considered miRNA-target gene associations that have
been verified using reporter assays. The respective 199
interactions between the miRNAs and target genes have
been extracted from the miRTarBase. The interaction
graph is presented in Figure 5, showing miRNAs as orange
nodes and target genes as blue nodes with the node sizes
representing the degree (i.e., the number of neighbors)
of the miRNAs and target genes. Of high interest arees and target genes that have been detected by reporter assays as
des. In particular, the large blue nodes, i.e., genes that are regulated by
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CDKN1A, VEGFA, PTEN, and E2F1 were regulated by
at least five miRNAs, VEGFA and CDKN1A even by seven
different miRNAs. A further seven genes were regulated
by four miRNAs: TGFBR2, RB1, CCND1, APP, BCL2,
ESR1, MAPK9. To understand whether the regulated
genes have a common biological meaning we carried
out a network enrichment analysis using GeneTrail
using the KEGG database [34]. We discovered signifi-
cant associations with various different pathologies ana-
lyzed in our study. Most prominently, 32 target genes
were related to pathways in cancer. Although these re-
sults do not demonstrate a direct relation between the
miRNAs and the diseases on a functional level, the re-
sults indicate a potential key role of the disease-affected
miRNAs in human pathogenic processes.
Discussion
For most diseases, early and specific markers are lacking.
Hence, besides the continuous refinement of existing
biomarkers, the search for novel, early disease predictors
belongs to the current challenges in biomarker research.
miRNAs offer a new class of biologically active molecules
that contribute to many disease processes and compensa-
tory mechanisms. Accordingly, they might not only offer
the ability to detect a disease early, but could also comple-
ment existing molecular and clinical markers by providing
additional information, supporting a biomarker-guided
differential diagnosis. Furthermore, miRNA signatures
could support a differential diagnosis in clinically over-
lapping diseases, such as non-ischemic systolic heart
failure versus acute myocardial infarction. Consequently,
miRNAs are increasingly recognized as valuable bio-
markers for different pathologies. However, in most
studies, a case–control scenario has been applied and
comprehensive comparisons between different diseases
are largely missing.
The current meta-analysis aimed to compare the
miRNA profiles from 1,049 samples belonging to 19
different diseases as well as controls. Here, we not only
identified disease-specific miRNAs but also miRNAs asso-
ciated with the presence of a disease in general. Moreover,
we were able to show that miRNA patterns improve the
diagnostic accuracy substantially and provide the required
specificity for diagnostic purposes.
In the present study, we found many miRNAs that
were either up- or downregulated in the majority of dis-
eases compared to controls. Interestingly, among the
most significant miRNAs downregulated in about 70%
(13 of 19) of the analyzed diseases we found members of
the miR-17 family, i.e., hsa-miR-17 and hsa-miR-106b. It
is known that members of this family are over-expressed
in cancer tissue and thus act as oncogenes by promot-
ing cell proliferation, suppression of apoptosis of cancercells, or induction of tumor angiogenesis [36]. Although
this observation appears to be in contradiction to our
data, one has to bear in mind that we analyzed blood
but not tissue. The same holds for hsa-miR-144*, which
was a key miRNA in our analysis and downregulated in
almost all tested disease conditions. According to the
Human MIRNA & Diseases Database (HMDD, [37,38])
several studies revealed hsa-miR-144* (in the current
V20 miRBase: hsa-miR-144-5p) as disease-associated. In
our recent study on Alzheimer’s disease, hsa-miR-144-5p
was the most significantly downregulated miRNA in
whole blood [28]. In addition, this miRNA was down-
regulated in esophageal biopsy specimens of eosinophilic
esophagitis patients [39]. In contrast, Liu et al. showed
that hsa-miR-144* is overexpressed in peripheral blood
mononuclear cells of active tuberculosis patients [40] and
Redova et al. showed that it is also upregulated in serum
of patients with renal cell carcinoma compared to healthy
controls [41]. hsa-miR-144* was further identified as a
new fecal-based marker for colon cancer [42] and as
significantly upregulated in primary medulloblastoma
samples compared to neural stem cells [43]. In the above-
mentioned studies, hsa-miR-144* has been described to be
upregulated in diseases. While it is known that blood- and
tissue-based regulation do not necessarily correlate [44],
likewise, blood-based patterns and serum-based patterns
for the same disease can vary substantially. There may be
different reasons for this observation. First, we did not
include infectious diseases in our study while Liu et al.
focused on tuberculosis patients. Second, different blood
collection and measurement systems have been applied in
both studies, potentially leading to a systemic bias compli-
cating a comparison between the studies. These heteroge-
neous results underline the need for a high degree of
standardization of blood collection, miRNA processing
protocols, measurement, and bioinformatics. In addition,
it is certainly advised to only relate miRNA data that have
been obtained by comparable conditions.
Next, we would like to address the origin of the miRNAs
that are generally up- or downregulated in diseases. In
a previous study, we compared the expression of up-,
down-, and not regulated miRNAs in CD14, CD15, CD19,
CD3, and CD56 positive cells [45]. The miRNAs that are
upregulated in diseases in the present study showed stron-
gest expression in CD19 cells in our previous study. The
downregulated miRNAs in diseases were predominantly
expressed in CD14, CD15, and CD56 cells. This holds es-
pecially for hsa-miR-144*, which was mostly expressed
in CD15 cells compared to the other cell types accord-
ing to the results of our previous study. Although the
aforementioned differences between up- and downregu-
lated miRNAs in general were statistically non-significant
(P >0.05), the results indicate that the miRNAs associated
with diseases are expressed at varying levels in different
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separation study have been collected in EDTA blood tubes
since PAXgene tubes lead to a cell lysis. As mentioned
in the previous paragraph, the differences in the blood
collection protocols will impact the comparison bet-
ween disease miRNAs and miRNAs expressed in diffe-
rent cell types.
The dataset used for our meta-analysis has been genera-
ted over three years and the samples have been collected
at nine different institutions. An obvious confounding
variable that also may limit the applicability of miRNAs in
clinical routine is the storage of samples over time. To
minimize this, we used PAXgene tubes containing RNA
stabilizing agents, allowing for storage of samples bet-
ween −20 to −70°C for up to 50 months. We addition-
ally checked the storage of RNA samples over a period
of up to four months at −20°C. After two months, we
still reached correlation of 0.89, which is well in the
range of the platform’s technical reproducibility for blood
samples. Even after four months, we still reached a correl-
ation of 0.865 (detail in Additional file 1: Figure S1). For
serum samples, we were even able to show the stability of
miRNA expression for much longer periods of time (up to
three decades) [16]. The highly consistent and significant
results obtained in our meta-analysis thus confirm the
robustness of the approach.
Although these results support the idea of miRNAs as
future diagnostic biomarkers, there are various aspects
that have to be considered. While a strength of our study
set-up is the parallel analysis of many human diseases, the
cohort sizes for some of the diseases analyzed is rather
small. Since a small cohort size may lead to an overesti-
mation of the actual clinical performance for the respect-
ive disease, the identified signatures await confirmation by
larger independent patient cohorts. Additionally, in pro-
spective studies, one needs to investigate the outcome
given clinical end-points associated with the different
disease signatures.
To develop diagnostic tests, it is important to consider
all information about the source of the miRNAs. The
association with diseases in general is only one factor
that needs to be taken into account when considering
miRNAs as disease-specific biomarkers. Confounding
biological factors, such as age or gender of patients, as
well as technical factors, such as storage conditions and
processing protocols, are also essential in order to
judge the value of miRNAs as biomarkers [46].
Another potential reason which may delay or even
hinder the translation into clinical routine is the measure-
ment system; miRNAs are relatively stable molecules and
their quantification can be achieved by different method-
ologies. As such, miRNA quantification by PCR-based ap-
proaches shows a very high dynamic range and allows for
absolute quantification, thus enabling testing in clinicalroutine. Furthermore, techniques for measuring sets of
miRNAs as qRT-PCR are relatively inexpensive, fast, and
established in most clinical laboratories, enabling testing
in clinical routine.
In summary, we present a substantial meta-analysis of
high-throughput miRNA data from patients’ blood sam-
ples. Our study presents miRNAs that are dysregulated in
almost all patients, such as miR-144*, which was also vali-
dated using qRT-PCR. However, the respective miRNAs
do not have to be omitted as specific markers for single
diseases. In combination with other miRNAs, these bio-
markers can add substantial diagnostic information to
disease-specific signatures. Moreover, we were able to
present specific miRNA patterns for all diseases and for
all inter-disease comparisons besides few cases such as the
separation of pancreatitis from pancreatic cancer. Finally,
we were able to report sets of miRNAs being dysregulated
in specific diseases, further promoting the investigation
of miRNAs from peripheral blood as clinically relevant
information carriers.Conclusions
In this study, we performed a meta-analysis of 1,049
miRNA profiles measured from whole blood samples.
We discovered miRNAs that seem to be generally asso-
ciated with diseases, most importantly miR-144*. This
miRNA was validated technically and in an independent
cohort of breast cancer patients by qRT-PCR. We pro-
vided first evidence that specific miRNA patterns exist
for all diseases. Additionally, we report a set of miRNAs
that seem to be rather robust in the patient’s blood.
Our study underscores the potential of miRNA signa-
tures for diseases. To translate respective biomarker sets
into clinical practice, further validation studies on in-
dependent cohorts are however essential. Finally, it is
crucial to follow strict standards in blood collection and
measurement of miRNA profiles in order to minimize
technical bias.Additional file
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